Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Massimo Broggini
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Anatomy
Chemicals & Drugs
Living Beings
Genes & Molecular Sequences
Physiology
Sign-in to see full Profile
Network (preview)
48
D'Incalci, Maurizio
26
Marchini, Sergio
17
Vikhanskaya, Faina
14
Erba, Eugenio
13
Codegoni, Annamaria
11
Geroni, Cristina
9
Marabese, Mirko
8
Damia, Giovanna
7
Mangioni, Costantino
7
Marrazzo, Eleonora
6
Giavazzi, Raffaella
5
Faircloth, Glynn
5
Vignati, Sara
4
Mongelli, Nicola
4
Parodi, Stefano
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Massimo Broggini (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Marrazzo E; Marchini S; Tavecchio M; Alberio T; Previdi S; Erba E; Rotter V; Broggini M
The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy.
European journal of cancer (Oxford, England : 1990) 2009;45(3):443-53.
-
2008: Marchini Sergio; Mariani Pietro; Chiorino Giovanna; Marrazzo Eleonora; Bonomi Riccardo; Fruscio Robert; Clivio Luca; Garbi Annalisa; Torri Valter; Cinquini Michela; Dell'Anna Tiziana; Apolone Giovanni; Broggini Massimo; D'Incalci Maurizio
Analysis of gene expression in early-stage ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7850-60.
-
2008: Ganzinelli Monica; Carrassa Laura; Crippa Francesca; Tavecchio Michele; Broggini Massimo; Damia Giovanna
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5131-41.
-
2008: Marabese M; Mazzoletti M; Vikhanskaya F; Broggini M
HtrA2 enhances the apoptotic functions of p73 on bax.
Cell death and differentiation 2008;15(5):849-58.
-
2008: Marchini S; Marabese M; Marrazzo E; Mariani P; Cattaneo D; Fossati R; Compagnoni A; Fruscio R; Lissoni A A; Broggini M
DeltaNp63 expression is associated with poor survival in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):501-7.
-
2008: Cooper W N; Dickinson R E; Dallol A; Grigorieva E V; Pavlova T V; Hesson L B; Bieche I; Broggini M; Maher E R; Zabarovsky E R; Clark G J; Latif F
Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.
Oncogene 2008;27(12):1805-11.
-
2008: Marabese Mirko; Marchini Sergio; Marrazzo Eleonora; Mariani Pietro; Cattaneo Dario; Fossati Roldano; Compagnoni Anna; Signorelli Mauro; Moll Ute M; Codegoni A Maria; Broggini Massimo
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2008;44(1):131-41.
-
2007: Rampino Teresa; Gregorini Marilena; Guidetti Cristina; Broggini Massimo; Marchini Sergio; Bonomi Riccardo; Maggio Milena; Roscini Elisabetta; Soccio Grazia; Tiboldo Renza; Dal Canton Antonio
KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells.
Growth factors (Chur, Switzerland) 2007;25(6):382-91.
-
2007: Zangrossi Stefano; Marabese Mirko; Broggini Massimo; Giordano Rosaria; D'Erasmo Marco; Montelatici Elisa; Intini Daniela; Neri Antonino; Pesce Maurizio; Rebulla Paolo; Lazzari Lorenza
Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker.
Stem cells (Dayton, Ohio) 2007;25(7):1675-80.
-
2007: Marabese Mirko; Vikhanskaya Faina; Broggini Massimo
p73: a chiaroscuro gene in cancer.
European journal of cancer (Oxford, England : 1990) 2007;43(9):1361-72.
-
2007: Sabatino Maria Antonietta; Previdi Sara; Broggini Massimo
In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs.
International journal of cancer. Journal international du cancer 2007;120(3):506-13.
-
2007: Vikhanskaya Faina; Lee Ming Kei; Mazzoletti Marco; Broggini Massimo; Sabapathy Kanaga
Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.
Nucleic acids research 2007;35(6):2093-104.
-
2006: Marrazzo Eleonora; Marchini Sergio; Previdi Sara; Broggini Massimo
Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or not.
Cancer biology & therapy 2006;5(7):794-803.
-
2005: Polato Federica; Codegoni Annamaria; Fruscio Robert; Perego Patrizia; Mangioni Costantino; Saha Saurabh; Bardelli Alberto; Broggini Massimo
PRL-3 phosphatase is implicated in ovarian cancer growth.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6835-9.
-
2005: Maffucci Tania; Piccolo Enza; Cumashi Albana; Iezzi Manuela; Riley Andrew M; Saiardi Adolfo; Godage H Yasmin; Rossi Cosmo; Broggini Massimo; Iacobelli Stefano; Potter Barry V L; Innocenti Paolo; Falasca Marco
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
Cancer research 2005;65(18):8339-49.
-
2005: Marabese M; Marchini S; Sabatino M A; Polato F; Vikhanskaya F; Marrazzo E; Riccardi E; Scanziani E; Broggini M
Effects of inducible overexpression of DNp73alpha on cancer cell growth and response to treatment in vitro and in vivo.
Cell death and differentiation 2005;12(7):805-14.
-
2005: Vikhanskaya Faina; Siddique Mobin M; Kei Lee Ming; Broggini Massimo; Sabapathy Kanaga
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4348-56.
-
2005: Manenti Luigi; Riccardi Elena; Marchini Sergio; Naumova Elitza; Floriani Irene; Garofalo Angela; Dossi Romina; Marrazzo Eleonora; Ribatti Domenico; Scanziani Eugenio; Bani Mariarosa; Belotti Dorina; Broggini Massimo; Giavazzi Raffaella
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
Molecular cancer therapeutics 2005;4(5):715-25.
-
2005: Marchini S; Marrazzo E; Bonomi R; Chiorino G; Zaffaroni M; Weissbach L; Hornicek F J; Broggini M; Faircloth G T; D'Incalci M
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
European journal of cancer (Oxford, England : 1990) 2005;41(2):323-33.
-
2004: Damia Giovanna; Broggini Massimo
Improving the selectivity of cancer treatments by interfering with cell response pathways.
European journal of cancer (Oxford, England : 1990) 2004;40(17):2550-9.
-
2004: Carrassa Laura; Broggini Massimo; Erba Eugenio; Damia Giovanna
Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.
Cell cycle (Georgetown, Tex.) 2004;3(9):1177-81.
-
2004: Taraboletti G; Poli M; Dossi R; Manenti L; Borsotti P; Faircloth G T; Broggini M; D'Incalci M; Ribatti D; Giavazzi R
Antiangiogenic activity of aplidine, a new agent of marine origin.
British journal of cancer 2004;90(12):2418-24.
-
2004: Marchini S; D'Incalci M; Broggini M
New molecules and strategies in the field of anticancer agents.
Current medicinal chemistry. Anti-cancer agents 2004;4(3):247-62.
-
2004: Piccolo Enza; Vignati Sara; Maffucci Tania; Innominato Pasquale F; Riley Andrew M; Potter Barry V L; Pandolfi Pier Paolo; Broggini Massimo; Iacobelli Stefano; Innocenti Paolo; Falasca Marco
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Oncogene 2004;23(9):1754-65.
-
2004: Broggini Massimo; Marchini Sergio; Fontana Erminia; Moneta Donatella; Fowst Camilla; Geroni Cristina
Brostallicin: a new concept in minor groove DNA binder development.
Anti-cancer drugs 2004;15(1):1-6.
-
2004: Damia Giovanna; Broggini Massimo
Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.
Cell cycle (Georgetown, Tex.) 2004;3(1):46-50.
-
2003: Sabatino Maria Antonietta; Colombo Tina; Geroni Cristina; Marchini Sergio; Broggini Massimo
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5402-8.
-
2003: Marabese Mirko; Vikhanskaya Faina; Rainelli Cristina; Sakai Toshiyuki; Broggini Massimo
DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1.
Nucleic acids research 2003;31(22):6624-32.
-
2003: Carrassa Laura; Broggini Massimo; Vikhanskaya Faina; Damia Giovanna
Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites.
Cell cycle (Georgetown, Tex.) 2003;2(6):604-9.
-
2003: Erba E; Serafini M; Gaipa G; Tognon G; Marchini S; Celli N; Rotilio D; Broggini M; Jimeno J; Faircloth G T; Biondi A; D'Incalci M
Effect of Aplidin in acute lymphoblastic leukaemia cells.
British journal of cancer 2003;89(4):763-73.
-
2003: Polato F; Broggini M
Microsatellite instability and genetic alterations in ovarian cancer.
Minerva ginecologica 2003;55(2):129-38.
-
2003: Broggini M; Marchini S V; Galliera E; Borsotti P; Taraboletti G; Erba E; Sironi M; Jimeno J; Faircloth G T; Giavazzi R; D'Incalci M
Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):52-9.
-
2002: Geroni Cristina; Marchini Sergio; Cozzi Paolo; Galliera Emanuela; Ragg Enzio; Colombo Tina; Battaglia Rosangela; Howard Martin; D'Incalci Maurizio; Broggini Massimo
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Cancer research 2002;62(8):2332-6.
-
2002: Vignati S; Codegoni A; Polato F; Broggini M
Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs.
European journal of cancer (Oxford, England : 1990) 2002;38(1):177-83.
-
2002: Vikhanskaya Faina; Broggini Massimo
Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients.
International review of cytology 2002;219():157-98.
-
2001: Vikhanskaya F; Bani M R; Borsotti P; Ghilardi C; Ceruti R; Ghisleni G; Marabese M; Giavazzi R; Broggini M; Taraboletti G
p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.
Oncogene 2001;20(50):7293-300.
-
2001: Marchini S; Broggini M; Sessa C; D'Incalci M
Development of distamycin-related DNA binding anticancer drugs.
Expert opinion on investigational drugs 2001;10(9):1703-14.
-
2001: Alvi A J; Rader J S; Broggini M; Latif F; Maher E R
Microsatellite instability and mutational analysis of transforming growth factor beta receptor type II gene (TGFBR2) in sporadic ovarian cancer.
Molecular pathology : MP 2001;54(4):240-3.
-
2001: Damia G; Sanchez Y; Erba E; Broggini M
DNA Damage Induces p53-dependent Down-regulation of hCHK1.
The Journal of biological chemistry 2001;276(14):10641-5.
-
2001: Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C
4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.
Cancer research 2001;61(5):1991-5.
-
2001: Vikhanskaya F; Marchini S; Marabese M; Galliera E; Broggini M
P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.
Cancer research 2001;61(3):935-8.
-
2001: Damia G; Filiberti L; Vikhanskaya F; Carrassa L; Taya Y; D'incalci M; Broggini M
Cisplatinum and taxol induce different patterns of p53 phosphorylation.
Neoplasia (New York, N.Y.) 2001;3(1):10-6.
-
2000: Broggini M; Buraggi G; Brenna A; Riva L; Codegoni A M; Torri V; Lissoni A A; Mangioni C; D'Incalci M
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients.
Anticancer research 2000;20(6C):4835-40.
-
2000: Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(12):6780-4.
-
2000: Razzini G; Berrie C P; Vignati S; Broggini M; Mascetta G; Brancaccio A; Falasca M
Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000;14(9):1179-87.
-
2000: De Feudis P; Vignati S; Rossi C; Mincioni T; Giavazzi R; D'Incalci M; Broggini M
Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.
Neoplasia (New York, N.Y.) 2000;2(3):202-7.
-
2000: Vikhanskaya F; D'Incalci M; Broggini M
p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Nucleic acids research 2000;28(2):513-9.
-
1999: Bertoni F; Codegoni A M; Furlan D; Tibiletti M G; Capella C; Broggini M
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers.
Genes, chromosomes & cancer 1999;26(2):176-80.
-
1999: Fullwood P; Marchini S; Rader J S; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher E R; Latif F
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Cancer research 1999;59(18):4662-7.
-
1999: Codegoni A M; Bertoni F; Patregnani C; Marinetti E; D'Incalci M; Broggini M
Allelic expression of p73 in human ovarian cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):949-53.
-
1999: Marchini S; Cirò M; Gallinari F; Geroni C; Cozzi P; D'Incalci M; Broggini M
Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
British journal of cancer 1999;80(7):991-7.
-
1999: Colella G; Marchini S; D'Incalci M; Brown R; Broggini M
Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents.
British journal of cancer 1999;80(3-4):338-43.
-
1999: Vikhanskaya F; Colella G; Valenti M; Parodi S; D'Incalci M; Broggini M
Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(4):937-41.
-
1999: Marchini S; Ciro' M; Broggini M
P53-independent caspase-mediated apoptosis in human leukaemic cells is induced by a DNA minor groove binder with antineoplastic activity.
Apoptosis : an international journal on programmed cell death 1999;4(1):39-45.
-
1999: Codegoni A M; Bertoni F; Colella G; Caspani G; Grassi L; D'Incalci M; Broggini M
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer.
Oncology research 1999;11(7):297-301.
-
1998: Codegoni A M; Nicoletti M I; Buraggi G; Valoti G; Giavazzi R; D'Incalci M; Landoni F; Maneo A; Broggini M
Molecular characterisation of a panel of human ovarian carcinoma xenografts.
European journal of cancer (Oxford, England : 1990) 1998;34(9):1432-8.
-
1998: Vikhanskaya F; Vignati S; Beccaglia P; Ottoboni C; Russo P; D'Incalci M; Broggini M
Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Experimental cell research 1998;241(1):96-101.
-
1998: Colella G; Vikhanskaya F; Codegoni A M; Bonazzi C; D'Incalci M; Broggini M
hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors.
Carcinogenesis 1998;19(4):691-4.
-
1998: Marchini S; Cozzi P; Beria I; Geroni C; Capolongo L; D'Incalci M; Broggini M
Sequence-specific DNA alkylation of novel tallimustine derivatives.
Anti-cancer drug design 1998;13(3):193-205.
-
1998: Codegoni A M; Castagna S; Mangioni C; Scovassi A I; Broggini M; D'Incalci M
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):313-9.
-
1997: Vikhanskaya F; Clerico L; Valenti M; Stanzione M S; Broggini M; Parodi S; Russo P
Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.
International journal of cancer. Journal international du cancer 1997;72(1):155-9.
-
1997: Bonfanti M; Colella G; Broggini M; D'Incalci M
Effect of G:C-->A:T transition, potentially arising from O6-guanine alkylation, in the transcription regulation of c-fos serum response element.
Anticancer research 1997;17(3C):2019-24.
-
1997: Bonfanti M; Taverna S; Salmona M; D'Incalci M; Broggini M
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.
Cancer research 1997;57(8):1442-6.
-
1997: Codegoni A M; Broggini M; Pitelli M R; Pantarotto M; Torri V; Mangioni C; D'Incalci M
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
Gynecologic oncology 1997;65(1):130-7.
-
1997: Debernardis D; Siré E G; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Cancer research 1997;57(5):870-4.
-
1997: De Feudis P; Debernardis D; Beccaglia P; Valenti M; Graniela Siré E; Arzani D; Stanzione S; Parodi S; D'Incalci M; Russo P; Broggini M
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
British journal of cancer 1997;76(4):474-9.
-
1997: Marchini S; Codegoni A M; Bonazzi C; Chiari S; Broggini M
Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
British journal of cancer 1997;76(2):146-9.
-
1996: Vikhanskaya F; Erba E; D'Incalci M; Broggini M
Changes in cyclins and cyclin-dependent kinases induced by DNA damaging agents in a human ovarian cancer cell line expressing mutated or wild-type P53.
Experimental cell research 1996;227(2):380-5.
-
1995: Marchini S; Gonzalez Paz O; Ripamonti M; Geroni C; Bargiotti A; Caruso M; Todeschi S; D'Incalci M; Broggini M
Sequence-specific DNA interactions by novel alkylating anthracycline derivatives.
Anti-cancer drug design 1995;10(8):641-53.
-
1995: Vikhanskaya F; D'Incalci M; Broggini M
Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes.
International journal of cancer. Journal international du cancer 1995;61(3):397-401.
-
1995: Conforti G; Codegoni A M; Scanziani E; Dolfini E; Dasdia T; Calza M; Caniatti M; Broggini M
Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin.
British journal of cancer 1995;71(3):505-11.
-
1995: Cattabeni M; D'Incalci M; Broggini M
Differential expression of c-fos proto-oncogene in two subclones derived from a human ovarian cancer cell line.
Cellular and molecular biology (Noisy-le-Grand, France) 1995;41(2):255-63.
-
1995: Broggini M; Coley H M; Mongelli N; Pesenti E; Wyatt M D; Hartley J A; D'Incalci M
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin.
Nucleic acids research 1995;23(1):81-7.
-
1994: Broggini M; D'Incalci M
Modulation of transcription factor--DNA interactions by anticancer drugs.
Anti-cancer drug design 1994;9(4):373-87.
-
1994: Vikhanskaya F; Erba E; D'Incalci M; Broggini M
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53.
Nucleic acids research 1994;22(6):1012-7.
-
1994: Geroni C; Pesenti E; Broggini M; Belvedere G; Tagliabue G; D'Incalci M; Pennella G; Grandi M
L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
British journal of cancer 1994;69(2):315-9.
-
1993: Vikhanskaya F; D'Incalci M; Broggini M
Effects of DNA damaging agents on gene expression in two human cancer cell lines.
Cellular and molecular biology (Noisy-le-Grand, France) 1993;39(8):855-62.
-
1993: Capolongo L; Melegaro G; Broggini M; Mongelli N; Grandi M
Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).
British journal of cancer 1993;68(5):916-9.
-
1993: Fabbri S; Prontera C; Broggini M; D'Incalci M
Differential inhibition of the DNA binding of transcription factors NF kappa B and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications.
Carcinogenesis 1993;14(9):1963-7.
-
1993: Geroni C; Pesenti E; Tagliabue G; Ballinari D; Mongelli N; Broggini M; Erba E; D'Incalci M; Spreafico F; Grandi M
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies.
International journal of cancer. Journal international du cancer 1993;53(2):308-14.
-
1991: Bonfanti M; Broggini M; Prontera C; D'Incalci M
O6-methylguanine inhibits the binding of transcription factors to DNA.
Nucleic acids research 1991;19(20):5739-42.
-
1991: Balconi G; Pang Y; Broggini M; Morali F; Marzola M; Erba E; Ponti M; Spinelli L; Mangioni C; Redaelli L
Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer.
British journal of cancer 1991;64(2):288-92.
-
1991: Broggini M; Erba E; Ponti M; Ballinari D; Geroni C; Spreafico F; D'Incalci M
Selective DNA interaction of the novel distamycin derivative FCE 24517.
Cancer research 1991;51(1):199-204.
-
1990: Broggini M; Hartley J A; Mattes W B; Ponti M; Kohn K W; D'Incalci M
DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)
British journal of cancer 1990;61(2):285-9.
-
1989: Broggini M; Ponti M; Ottolenghi S; D'Incalci M; Mongelli N; Mantovani R
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements.
Nucleic acids research 1989;17(3):1051-9.
-
1989: D'Incalci M; Balconi G; Broggini M; Colombo T; Marzola M; Morali F; Pang Y; Sen S; Spinelli L
Problems in the design of anticancer agents.
Cancer surveys 1989;8(3):535-55.
-
1988: Broggini M; Grandi M; Ubezio P; Geroni C; Giuliani F C; D'Incalci M
Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.
Biochemical pharmacology 1988;37(23):4423-31.
-
1988: Catapano C V; Guaitani A; Broggini M; Corada M; Bartosek I; Italia C; Donelli M G
Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats.
Anticancer research 1988;8(4):725-31.
-
1988: Balconi G; Broggini M; Erba E; D'Incalci M; Colombo N; Mangioni C; Bertolero F
Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitro.
International journal of cancer. Journal international du cancer 1988;41(6):809-18.
-
1988: Broggini M; Balconi G; Bertolero F; Erba E; Landoni F; Mangioni C; D'Incalci M
DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture.
Biochemical pharmacology 1988;37(9):1835-6.
-
1988: Erba E; Ubezio P; Broggini M; Ponti M; D'Incalci M
DNA damage, cytotoxic effect and cell-cycle perturbation of Hoechst 33342 on L1210 cells in vitro.
Cytometry 1988;9(1):1-6.
-
1987: Catapano C V; Broggini M; Erba E; Ponti M; Mariani L; Citti L; D'Incalci M
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
Cancer research 1987;47(18):4884-9.
-
1984: Broggini M; Italia C; Colombo T; Marmonti L; Donelli M G
Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.
Cancer treatment reports 1984;68(5):739-47.
Sign-in to see more
